Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Eisai Inc.
Genentech, Inc.
Information provided by (Responsible Party):
Rachel Freedman, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01912963
First received: July 24, 2013
Last updated: August 28, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: January 2021
  Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)